Floatz logo

IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER

Cutaneous Tumor

Ankyra Therapeutics, Incmonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Cutaneous Tumor cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 4BB
Rapamycin
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 4BB
TACROLIMUS
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 4BB
Nivolumab
UNICANCER
Phase 2B
Imatinib
M.D. Anderson Cancer Center
Phase 2B

View all 24 →

Same molecule, other indications

IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
68 / 100
View asset →
skin squamous cell carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
lung cancerDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →